4.8 Article

Structural Basis of Sarco/Endoplasmic Reticulum Ca2+-ATPase 2b Regulation via Transmembrane Helix Interplay

Journal

CELL REPORTS
Volume 27, Issue 4, Pages 1221-+

Publisher

CELL PRESS
DOI: 10.1016/j.celrep.2019.03.106

Keywords

-

Categories

Funding

  1. CREST, JST [JPMJCR13M6]
  2. MEXT [15H04335, 26116005, 26119007]
  3. Takeda Science Foundation
  4. Platform Project for Supporting Drug Discovery and Life Science Research/Platform for Drug Discovery, Informatics, and Structural Life Science (PDIS) from the Japan Agency for Medical Research and Development (AMED)
  5. Platform Project for Supporting Drug Discovery and Life Science Research (Basis for Supporting Innovative Drug Discovery and Life Science Research [BINDS]) from AMED [JP18am0101075, JP18am0101078]
  6. Grants-in-Aid for Scientific Research [15H04335, 26116005, 26119007] Funding Source: KAKEN

Ask authors/readers for more resources

Sarco/endoplasmic reticulum (ER) Ca2+-ATPase 2b (SERCA2b) is a ubiquitously expressed membrane protein that facilitates Ca2+ uptake from the cytosol to the ER. SERCA2b includes a characteristic 11th transmembrane helix (TM11) followed by a luminal tail, but the structural basis of SERCA regulation by these C-terminal segments remains unclear. Here, we determined the crystal structures of SERCA2b and its C-terminal splicing variant SERCA2a, both in the E1-2Ca(2+)-adenyly1 methylenediphosphonate (AMPPCP) state. Despite discrepancies with the previously reported structural model of SERCA2b, TM11 was found to be located adjacent to TM10 and to interact weakly with a part of the L8/9 loop and the N-terminal end of TM10, thereby inhibiting the SERCA2b catalytic cycle. Accordingly, mutational disruption of the interactions between TM11 and its neighboring residues caused SERCA2b to display SERCA2a-like ATPase activity. We propose that TM11 serves as a key modulator of SERCA2b activity by fine-tuning the intramolecular interactions with other transmembrane regions.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Medicine, Research & Experimental

Antitumor activities of a defucosylated anti-EpCAM monoclonal antibody in colorectal carcinoma xenograft models

Guanjie Li, Hiroyuki Suzuki, Tomokazu Ohishi, Teizo Asano, Tomohiro Tanaka, Miyuki Yanaka, Takuro Nakamura, Takeo Yoshikawa, Manabu Kawada, Mika K. K. Kaneko, Yukinari Kato

Summary: EpCAM is a type I transmembrane glycoprotein highly expressed on tumor cells, and it has been considered as a promising target for tumor diagnosis and therapy. In this study, a defucosylated version of an anti-EpCAM monoclonal antibody was generated and evaluated for its antitumor activity against EpCAM-positive cells. The results showed that the antibody exhibited potent cytotoxicity for EpCAM-overexpressing cells and suppressed tumor development in xenograft mouse models.

INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE (2023)

Review Biochemistry & Molecular Biology

Current Targeted Therapy for Metastatic Colorectal Cancer

Tomokazu Ohishi, Mika K. Kaneko, Yukihiro Yoshida, Atsuo Takashima, Yukinari Kato, Manabu Kawada

Summary: Colorectal cancer (CRC) is one of the most common and deadly types of cancer worldwide. Traditional treatment options for metastatic CRC (mCRC) were surgery or surgery combined with radiation and/or chemotherapy. However, the development of targeted drugs like cetuximab and bevacizumab has significantly improved patients' overall survival. This review discusses the latest molecular evidence and FDA-approved targeted drugs for mCRC, as well as their mechanisms of action and implications for treatment selection.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Article Biochemistry & Molecular Biology

A Novel Anti-CD44 Variant 3 Monoclonal Antibody C44Mab-6 Was Established for Multiple Applications

Hiroyuki Suzuki, Kaishi Kitamura, Nohara Goto, Kenichiro Ishikawa, Tsunenori Ouchida, Tomohiro Tanaka, Mika K. Kaneko, Yukinari Kato

Summary: CD44 promotes tumor progression by recruiting growth factors and acquiring stemness, invasiveness, and drug resistance. We have established various anti-CD44s and anti-CD44v monoclonal antibodies through immunization and in this study, we developed C(44)Mab-6, which could detect CD44v3 in various experiments and has potential applications in tumor diagnosis and therapy.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Article Multidisciplinary Sciences

Zinc homeostasis governed by Golgi-resident ZnT family members regulates ERp44-mediated proteostasis at the ER-Golgi interface

Yuta Amagai, Momo Yamada, Toshiyuki Kowada, Tomomi Watanabe, Yuyin Du, Rong Liu, Satoshi Naramoto, Satoshi Watanabe, Junko Kyozuka, Tiziana Anelli, Tiziana Tempio, Roberto Sitia, Shin Mizukami, Kenji Inaba

Summary: Using super-resolution microscopy and Zn2+-probes targeted in specific Golgi subregions, this study reveals that Golgi-resident zinc transporters ZnT4, ZnT5/ZnT6, and ZnT7 regulate labile Zn2+ concentration at different regions of the Golgi, and their Zn2+ fluxes control the localization, trafficking, and client-retrieval activity of ERp44 along the early secretory pathway.

NATURE COMMUNICATIONS (2023)

Article Oncology

Enhanced Systemic Antitumour Immunity by Hypofractionated Radiotherapy and Anti-PD-L1 Therapy in Dogs with Pulmonary Metastatic Oral Malignant Melanoma

Tatsuya Deguchi, Naoya Maekawa, Satoru Konnai, Ryo Owaki, Kenji Hosoya, Keitaro Morishita, Motoji Nakamura, Tomohiro Okagawa, Hiroto Takeuchi, Sangho Kim, Ryohei Kinoshita, Yurika Tachibana, Madoka Yokokawa, Satoshi Takagi, Yukinari Kato, Yasuhiko Suzuki, Shiro Murata, Kazuhiko Ohashi

Summary: Immune checkpoint inhibitors (ICIs) show promise as a treatment option for canine cancers. However, the safety and efficacy of combining ICIs with radiation therapy have not been reported in dogs. A retrospective analysis of dogs with metastatic melanoma suggests that prior hypofractionated radiation therapy can enhance the response to anti-PD-L1 immunotherapy. Further studies are needed to confirm these findings.

CANCERS (2023)

Article Immunology

Enhancement of Vaccine-Induced T-Cell Responses by PD-L1 Blockade in Calves

Tomohiro Okagawa, Satoru Konnai, Hayato Nakamura, Otgontuya Ganbaatar, Yamato Sajiki, Kei Watari, Haruka Noda, Mitsuru Honma, Yukinari Kato, Yasuhiko Suzuki, Naoya Maekawa, Shiro Murata, Kazuhiko Ohashi

Summary: Blocking the interaction between PD-1 and PD-L1 can enhance T-cell responses induced by vaccination in cattle, suggesting the potential utility of anti-PD-L1 Ab in improving vaccination efficacy.

VACCINES (2023)

Article Immunology

EMab-300 Detects Mouse Epidermal Growth Factor Receptor-Expressing Cancer Cell Lines in Flow Cytometry

Nohara Goto, Hiroyuki Suzuki, Tomohiro Tanaka, Kenichiro Ishikawa, Tsunenori Ouchida, Mika K. Kaneko, Yukinari Kato

Summary: In this study, a specific and sensitive monoclonal antibody (mAb) for mouse EGFR (mEGFR) was developed using the Cell-Based Immunization and Screening (CBIS) method. The established antibody, EMab-300, showed reactivity with mEGFR-overexpressed cell lines using flow cytometry. The results suggest that EMab-300 can be used for the detection of mEGFR and may have potential applications in preclinical studies.

ANTIBODIES (2023)

Article Immunology

Development of a Novel Anti-CD44 Variant 5 Monoclonal Antibody C44Mab-3 for Multiple Applications against Pancreatic Carcinomas

Yuma Kudo, Hiroyuki Suzuki, Tomohiro Tanaka, Mika K. Kaneko, Yukinari Kato

Summary: Pancreatic cancer has a poor prognosis due to the lack of early diagnostic biomarkers and resistance to chemotherapy. CD44 is a cancer stem cell marker and plays various roles in tumor promotion and drug resistance. This study successfully established a specific monoclonal antibody for CD44v5, which has potential applications in the diagnosis and therapy of pancreatic cancer.

ANTIBODIES (2023)

Article Oncology

Promotion of squamous cell carcinoma tumorigenesis by oncogene-mediated THG-1/TSC22D4 phosphorylation

Nohara Goto, Hiroyuki Suzuki, Ling Zheng, Yasuhito Okano, Yukari Okita, Yukihide Watanabe, Yukinari Kato, Mitsuyasu Kato

Summary: This study revealed that THG-1, a protein stimulated by transforming growth factor-beta 1 (TGF-β1), plays a crucial role in the proliferation, invasiveness, and tumor formation of squamous cell carcinomas (SCCs). THG-1 is phosphorylated by the receptor tyrosine kinase (RTK)-RAS- ERK pathway, which promotes oncogene-mediated tumorigenesis, and is involved in the alternative splicing of CD44 variants that regulate invasiveness, stemness, and oxidative stress resistance. The detection of THG-1 phosphorylation could be used for cancer diagnosis and therapy.

CANCER SCIENCE (2023)

Article Biochemical Research Methods

Recombinant production of antibody antigen-binding fragments with an N-terminal human growth hormone tag in mammalian cells

Yuriko Adachi, Mika K. Kaneko, Yukinari Kato, Terukazu Nogi

Summary: This study explores a method to prepare recombinant Fabs as secreted fusion proteins using a human growth hormone domain and an octa-histidine tag. The tagged Fabs can be purified using standard immobilized metal chelate affinity chromatography. The method allows for efficient production of diverse Fabs and the complete removal of tags while maintaining the native fold and binding affinity of the Fab.

PROTEIN EXPRESSION AND PURIFICATION (2023)

Article Immunology

Molecular characterization of immunoinhibitory factors PD-1/PD-L1 in sheep

Wisa Tiyamanee, Satoru Konnai, Tomohiro Okagawa, Yutaro Nojima, Otgontuya Ganbaatar, Naoya Maekawa, Rie Hasebe, Yumiko Kagawa, Yukinari Kato, Yasuhiko Suzuki, Shiro Murata, Kazuhiko Ohashi

Summary: Sheep have been utilized as a large animal model for studying infectious diseases, but the lack of staining antibodies and reagents has hindered the progress of immunological studies on sheep. Previous research showed that the PD-1/PD-L1 pathway plays a role in T-cell exhaustion and disease progression in bovine chronic infections, and blocking PD-1 and PD-L1 can restore T-cell functions in cattle. However, the immunological role of the PD-1/PD-L1 pathway in chronic diseases of sheep remains unknown.

VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY (2023)

Article Microbiology

N-linked glycosylation of flavivirus E protein contributes to viral particle formation

Kotaro Ishida, Hirokazu Yagi, Yukinari Kato, Eiji Morita

Summary: This study investigates the role of N-glycosylation of flaviviral structural proteins in viral particle formation and secretion and finds that the amount of glycosylation regulates the release of subviral particles. Glycosylation mainly affects pre-Golgi transport.

PLOS PATHOGENS (2023)

Article Oncology

A Humanized and Defucosylated Antibody against Podoplanin (humLpMab-23-f) Exerts Antitumor Activities in Human Lung Cancer and Glioblastoma Xenograft Models

Hiroyuki Suzuki, Tomokazu Ohishi, Mika K. Kaneko, Yukinari Kato

Summary: Podoplanin (PDPN) is a transmembrane sialo-glycoprotein that plays important roles in cancer progression and metastasis. A humanized and defucosylated monoclonal antibody (mAb) against PDPN (humLpMab-23-f) has been developed and shown to have antitumor activity in xenograft models of human tumor cells.

CANCERS (2023)

Article Biochemistry & Molecular Biology

Establishment of a Novel Anti-CD44 Variant 10 Monoclonal Antibody C(44)Mab-18 for Immunohistochemical Analysis against Oral Squamous Cell Carcinomas

Kenichiro Ishikawa, Hiroyuki Suzuki, Mika K. Kaneko, Yukinari Kato

Summary: This article investigates the expression of CD44 in head and neck squamous cell carcinoma (HNSCC) and identifies a monoclonal antibody (C(44)Mab-18) that can recognize CD44, which has great potential for cancer diagnosis and therapy.

CURRENT ISSUES IN MOLECULAR BIOLOGY (2023)

Article Biochemistry & Molecular Biology

A Novel Anti-CD44 Variant 9 Monoclonal Antibody C44Mab-1 Was Developed for Immunohistochemical Analyses against Colorectal Cancers

Mayuki Tawara, Hiroyuki Suzuki, Nohara Goto, Tomohiro Tanaka, Mika K. K. Kaneko, Yukinari Kato

Summary: Researchers developed a monoclonal antibody, C(44)Mab-1, which can sensitively and specifically detect the expression of CD44v9 in cancer. This antibody is useful for flow cytometry, western blotting, and immunohistochemistry to detect CD44v9 in colorectal cancer.

CURRENT ISSUES IN MOLECULAR BIOLOGY (2023)

No Data Available